Search Results for "migraine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for migraine. Results 61 to 67 of 67 total matches.

Acetaminophen Safety

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2002  (Issue 1142)
(Bristol-Myers Squibb) 250 mg 2 q6h Excedrin Migraine Tablets, Caplets, and Geltabs (Bristol-Myers Squibb ...
An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen (www.fda.gov, search "acetaminophen hepatotoxicity").
Med Lett Drugs Ther. 2002 Oct 28;44(1142):91-3 |  Show IntroductionHide Introduction

Telithromycin (Ketek) for Respiratory Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 2004  (Issue 1189)
to treat migraine; severe peripheral vasospasm has been reported with concurrent use of macrolides. When ...
Telithromycin (Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.
Med Lett Drugs Ther. 2004 Aug 16;46(1189):66-8 |  Show IntroductionHide Introduction

Acetaminophen Safety - Deja Vu

   
The Medical Letter on Drugs and Therapeutics • Jul 13, 2009  (Issue 1316)
Extra Strength 250 mg 2 q6h Excedrin Migraine Tablets, Caplets, and Geltabs 250 mg 2 Excedrin PM 500 ...
Concerns have surfaced again at the FDA and in the media about the safety of acetaminophen and the multiplicity of products on the market in the US that contain various amounts of it.
Med Lett Drugs Ther. 2009 Jul 13;51(1316):53-4 |  Show IntroductionHide Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
for OA and RA Also available in an oral solution (Elyxyb) for acute treatment of migraine $4.50 ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
in multiple prescription and OTC products for treatment of pain, cough, cold, flu, migraine, insomnia, etc ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
with cardiovascular disease, hypertension, diabetes, migraine, hyperthyroidism, closed-angle glaucoma, or bladder ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction